PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the overall safety and maximum dose of CI 1033
in combination with paclitaxel and carboplatin in patients with NSCLC.